Biovica International AB (publ) provided earnings guidance for the full year 2022. For the full year, the company expected sales to be lower due to the delay in processing of the 510(k) application.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.365 SEK | +3.05% |
|
-4.64% | -8.33% |
Jun. 28 | Biovica to Provide Biomarker Testing for US Biopharmaceutical Company | MT |
Jun. 28 | Biovica International Signs New Agreement Supporting Pharma Development | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.33% | 18.88M | |
-37.33% | 8.55B | |
+14.86% | 3.8B | |
+7.38% | 2.44B | |
-25.96% | 1.87B | |
-17.30% | 1.74B | |
+36.49% | 1.19B | |
+32.58% | 830M | |
-7.64% | 711M | |
-18.37% | 589M |
- Stock Market
- Equities
- BIOVIC B Stock
- News Biovica International AB
- Biovica International AB Provides Earnings Guidance for the Full Year 2022